{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T07:50:00Z","timestamp":1772956200666,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.lana.2025.101193","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:54:10Z","timestamp":1753714450000},"page":"101193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing \u226417 kg and \u226424 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study"],"prefix":"10.1016","volume":"49","author":[{"given":"Jonas Alex","family":"Saute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Muntadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Gurgel-Giannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soledad","family":"Monges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Holanda","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulian","family":"Alecu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janaina","family":"Martins de Lana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayla","family":"Mumneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MarianaHorn","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Rosa de Stefani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Miglorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"de Castro Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Rutkoski","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna Henriques","family":"Nehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Lu\u00edsa","family":"Dubiela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micaela","family":"Pauni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvina Gomez","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Corbaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Ciro","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Caires de Oliveira Achili Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina","family":"Santos Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2025.101193_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"15","key":"10.1016\/j.lana.2025.101193_bib2","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.lana.2025.101193_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/ijns10030056","article-title":"Systematic review of presymptomatic treatment for spinal muscular atrophy","volume":"10","author":"Cooper","year":"2024","journal-title":"Int J Neonatal Screen"},{"issue":"8","key":"10.1016\/j.lana.2025.101193_bib4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.lana.2025.101193_bib5","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn careening: a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.lana.2025.101193_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1179692","article-title":"Sociodemographic and clinical characteristics and access to health care in patients with spinal muscular atrophy in Argentina","volume":"14","author":"Vazquez","year":"2023","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.lana.2025.101193_bib7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1590\/0004-282x20190073","article-title":"Observations from a nationwide vigilance program in medical care for spinal muscular atrophy patients in Chile","volume":"77","author":"Alvarez","year":"2019","journal-title":"Arq Neuropsiquiatr"},{"issue":"3 Suppl 1","key":"10.1016\/j.lana.2025.101193_bib8","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2023-0126","article-title":"Neonatal screening for spinal muscular atrophy: a pilot study in Brazil","volume":"46","author":"Oliveira Netto","year":"2023","journal-title":"Genet Mol Biol"},{"issue":"9","key":"10.1016\/j.lana.2025.101193_bib9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/gt.2017.68","article-title":"Management of neuromuscular diseases and spinal muscular atrophy in Latin America","volume":"24","author":"Monges","year":"2017","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.lana.2025.101193_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200224","article-title":"Life-saving treatments for spinal muscular atrophy: global access and availability","volume":"14","author":"Armengol","year":"2024","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.lana.2025.101193_bib11","series-title":"Spinraza","year":"2024"},{"key":"10.1016\/j.lana.2025.101193_bib12","series-title":"Evrysdi","year":"2025"},{"key":"10.1016\/j.lana.2025.101193_bib13","series-title":"Zolgensma","year":"2025"},{"key":"10.1016\/j.lana.2025.101193_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"issue":"7\u20138","key":"10.1016\/j.lana.2025.101193_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41434-024-00456-y","article-title":"Gene replacement therapy for spinal muscular atrophy: safety and preliminary efficacy in a Brazilian cohort","volume":"31","author":"Mendon\u00e7a","year":"2024","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/j.lana.2025.101193_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jped.2024.07.011","article-title":"Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil","volume":"101","author":"de Albuquerque","year":"2025","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.lana.2025.101193_bib19","first-page":"1","volume":"82","author":"Zanoteli","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"issue":"12","key":"10.1016\/j.lana.2025.101193_bib20","first-page":"1","article-title":"A self-reported Brazilian registry of 5q-spinal muscular atrophy: data on natural history, genetic characteristics, and multidisciplinary care","volume":"82","author":"Mendon\u00e7a","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.lana.2025.101193_bib21","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2024AE1133","article-title":"Longitudinal data collection in pediatric and adult patients with 5q spinal muscular atrophy in Latin America: LATAM RegistrAME study - a clinical registry study protocol","volume":"22","author":"Batista","year":"2024","journal-title":"Einstein (Sao Paulo)"},{"key":"10.1016\/j.lana.2025.101193_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.20517\/rdodj.2024.02","article-title":"Newborn screening in Mexico and Latin America: present and future","volume":"3","author":"Gonzaga-Jauregui","year":"2024","journal-title":"Rare Dis Orphan Drugs J"},{"issue":"4","key":"10.1016\/j.lana.2025.101193_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1016\/j.lana.2025.101193_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lana.2025.101193_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"10","key":"10.1016\/j.lana.2025.101193_bib26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.lana.2025.101193_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.lana.2025.101193_bib28","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.lana.2025.101193_bib29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.lana.2025.101193_bib30","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210268","article-title":"Safety and efficacy of IV onasemnogene abeparvovec for pediatric patients with spinal muscular atrophy: the phase 3b SMART study","volume":"104","author":"McMillan","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.lana.2025.101193_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nmd.2024.07.004","article-title":"Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1","volume":"42","author":"Finnegan","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.lana.2025.101193_bib32","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lana.2025.101193_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"Pane","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.lana.2025.101193_bib34","article-title":"Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study","volume":"47","author":"Wei\u00df","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10.1016\/j.lana.2025.101193_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D'Silva","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.lana.2025.101193_bib36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s13023-024-03326-3","article-title":"Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment","volume":"19","author":"Desguerre","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.lana.2025.101193_bib38","first-page":"86","article-title":"WHO Motor Development Study: windows of achievement for six gross motor development milestones","volume":"450","year":"2006","journal-title":"Acta Paediatr Suppl"},{"issue":"2","key":"10.1016\/j.lana.2025.101193_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00417897","article-title":"A penetration-aspiration scale","volume":"11","author":"Rosenbek","year":"1996","journal-title":"Dysphagia"},{"issue":"10","key":"10.1016\/j.lana.2025.101193_bib40","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00415-015-7836-y","article-title":"Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS)","volume":"262","author":"Wada","year":"2015","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.lana.2025.101193_bib41","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/BPO.0b013e31820fc522","article-title":"Development and initial validation of the assessment of caregiver experience with neuromuscular disease","volume":"31","author":"Matsumoto","year":"2011","journal-title":"J Pediatr Orthop"},{"issue":"4","key":"10.1016\/j.lana.2025.101193_bib42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/jcm13040921","article-title":"Use of the assessment of caregiver experience with neuromuscular disease (ACEND) in spinal muscular atrophy","volume":"13","author":"Brown","year":"2024","journal-title":"J Clin Med"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X25002030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X25002030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:55:33Z","timestamp":1772920533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X25002030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"alternative-id":["S2667193X25002030"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2025.101193","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing \u226417 kg and \u226424 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2025.101193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101193"}}